Login to Your Account

CFDA clears JHL’s IND for studies of Rituximab biosimilar

By Carmen Ho
Staff Writer

Wednesday, April 5, 2017

HONG KONG – The CFDA recently accepted a clinical trial application to conduct phase I and phase III trials of rituximab biosimilar JHL1101, submitted by JHL Biotech Inc., a startup based in Zhubei City, Taiwan, and Wuhan, China.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription